Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program
Drugs - Real World Outcomes · 2026-03 · 13 (1) · 121-131
DOI: 10.1007/s40801-026-00539-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs - Real World Outcomes, online erschienen am 10.03.2026. Verfasst von Patrick J Kiel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, RURaL Lab for D&I Research in Cancer Disparities, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN, 479…. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Pharmacy Practice, RURaL Lab for D&I Research in Cancer Disparities, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN, 47907, USA.
- Indiana University, Indianapolis, IN, USA.
- Department of Pharmacy Practice, RURaL Lab for D&I Research in Cancer Disparities, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN, 47907, USA. mapreston@purdue.edu.
- Center for Health Excellence, Quality and Innovation (CHEQI), College of Pharmacy, Purdue University, Indianapolis, IN, USA. mapreston@purdue.edu.
Zitieren
APA
Kiel, P. J., McGiffin, M. W., Skaar, T. C., & Preston, M. A. (2026). Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program. Drugs - Real World Outcomes, 13(1), 121-131. https://doi.org/10.1007/s40801-026-00539-9
Vancouver
Kiel PJ, McGiffin MW, Skaar TC, Preston MA. Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program. Drugs - Real World Outcomes. 2026;13(1):121-131. doi:10.1007/s40801-026-00539-9
BibTeX
@article{Kiel2026,
author = {Kiel, Patrick J and McGiffin, Mark W and Skaar, Todd C and Preston, Michael A},
title = {Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program},
journal = {Drugs - Real World Outcomes},
year = {2026},
volume = {13},
number = {1},
pages = {121--131},
doi = {10.1007/s40801-026-00539-9}
}
EUVIMED